FCG Advisors’s Outlook Therapeutics OTLK Stock Holding History

FCG Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$11K	Buy	+773	New	+$17.2K	﹤0.01%	186

Other funds holding OTLK

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

FCG Advisors's OTLK Position: Q3 2020 in Review

FCG Advisors opened a new position in Outlook Therapeutics (OTLK) in Q3 2020: 773 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #186 among its holdings.

27 funds tracked by Wall St. Rank hold OTLK as of Q3 2020.

FCG Advisors held 773 shares of Outlook Therapeutics worth $11K as of Q3 2020.
Outlook Therapeutics was a new FCG Advisors position in Q3 2020.
Outlook Therapeutics made up ﹤0.01% of FCG Advisors's portfolio in Q3 2020, its #186 holding.
27 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.